Evidence map›Paper›PMID 31649670›Full record

ArticleFrontiers in immunology2019

Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.

Katharine Clark, Jessica Yau, Anja Bloom, Jing Wang, David J Venzon, Motoshi Suzuki, Lise Pasquet, Benjamin J Compton, Susanna L Cardell, Steven A Porcelli and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Katharine ClarkVaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States.
Jessica YauVaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States.
Anja BloomVaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States.
Jing WangDivision of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
David J VenzonBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States.
Motoshi SuzukiBiochemistry and Biophysics Center, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, United States.
Lise PasquetVaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States.
Benjamin J ComptonThe Ferrier Research Institute, Victoria University of Wellington, Wellington, New Zealand.
Susanna L CardellDepartment of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Steven A PorcelliDepartment of Microbiology and Immunology and Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States.
Gavin F PainterThe Ferrier Research Institute, Victoria University of Wellington, Wellington, New Zealand.
Dirk M ZajoncDivision of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Jay A BerzofskyVaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States.
Masaki TerabeNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States.

Funding

Precision Targeting of CD1-Restricted iNKT Cells for Cancer ImmunotherapyR01AI045889 · NIAID · YESHIVA UNIVERSITY · PI Steven A Porcelli · 1999 to 2026
$9.3M
Host nutrients permit immune evasion of NKT cell anti-bacterial responsesR01AI137230 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI KRONENBERG, MITCHELL · 2018 to 2022
$3.1M
NIAID NIH HHS R01 AI045889NIAID NIH HHS R01 AI137230
6 · The paper itself

Abstract

iNKT cells are CD1d-restricted T cells recognizing lipid antigens. The prototypic iNKT cell-agonist α-galactosylceramide (α-GalCer) alongside compounds with similar structures induces robust proliferation and cytokine production of iNKT cells and protects against cancer

Indexed as

GalactosylceramidesAnimalsAntibodies, Monoclonal, Murine-DerivedAntigen PresentationAntigens, CD1dHumansMiceMice, Inbred BALB CNatural Killer T-CellsStructure-Activity Relationshipalpha-galactosylceramideAntibodies, Monoclonal, Murine-DerivedAntigens, CD1dCD1d antigen, mouseGalactosylceramidesalpha-galactosylceramidebeta-mannosylceramideCD1dL363natural killer T cells

Identifiers

PMID31649670
PMCPMC6794452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.